Preferred Label : KRAS G12C Inhibitor GH35;
NCIt definition : An orally bioavailable irreversible inhibitor of the oncogenic KRAS substitution mutation,
G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C
inhibitor GH35 selectively targets, binds to and inhibits the activity of the KRAS
G12C mutant, thereby inhibiting KRAS G12C mutant-dependent signaling. KRAS, a member
of the RAS family of oncogenes, serves an important role in cell signaling, division
and differentiation. Mutations of KRAS may induce constitutive signal transduction
leading to tumor cell growth, proliferation, invasion, and metastasis.;
Molecule name : GH-35; GH 35;
NCI Metathesaurus CUI : CL1771385;
Origin ID : C183160;
UMLS CUI : C5666906;
Semantic type(s)
- concept_is_in_subset
- has_target
